

POSTER PRESENTATION

Open Access

# P73. Functional characterisation of HBV-specific T cell receptors for redirection of T cells against HBV infected hepatocytes

K Krebs<sup>1\*</sup>, K Metzger<sup>1</sup>, L Weigand<sup>2</sup>, C Dargel<sup>1</sup>, E Kieback<sup>3</sup>, W Uckert<sup>3</sup>, D Busch<sup>4</sup>, A Krackhardt<sup>2</sup>, U Protzer<sup>1</sup>

From 1st Immunotherapy of Cancer Conference (ITOC1)  
Munich, Germany. 12-14 March 2014

Chronic HBV infection, which is accompanied by a weak and oligoclonal T cell response, is the most common cause of hepatocellular carcinoma (HCC). Current antiviral therapies do not eliminate the virus, but T cell therapy will very likely do so. From PBMCs of two HLA-A2<sup>+</sup> acutely infected patients and a donor who cleared HBV infection we have established several HBV-specific monoclonal T cell lines. Thereof we isolated 11 different T cell receptors (TCR) that are specific for the HBV S-protein derived peptides S20 (FLLTRILT1) and S172 (WLSLLVPFV) or for the C18 core-peptide (FLPSDFPSV). The aim of this study was a functional comparison of our set of HBV-specific TCRs in order to identify TCRs with optimal recognition of HBV peptides presented on HLA-A2.

By murinization and codon-optimisation of gene sequences of TCR a and b chains, fused by a P2A element for polycistronic expression, TCR expression after retroviral transduction was increased 2-fold to 60% of PBMCs expressing an HBV-specific TCR.

PBMCs transduced with the 11 optimised HBV-specific TCRs were compared in killing assays using peptide-pulsed T2 cells, LCLs and HBV-replicating HepG2.2.15 cells as targets. CD8<sup>+</sup> T cells transduced with the core-specific TCRs killed target cells loaded with 0.01 nM of peptide. Cells specific for the S20 and S172 peptide were less sensitive with a specific lysis as low as 0.1 nM. Expression of most of the HLA-A2 restricted HBV-specific TCRs in CD4<sup>+</sup> T cells also led to specific cytotoxicity, which was 10-fold reduced in sensitivity compared to CD8<sup>+</sup> T cells and independent of CD8 co-receptor binding. Notably,

our HBV-specific TCRs recognised peptide presented on various different HLA-A2 subtypes.

CD8<sup>+</sup> T cells transduced with HBV-specific TCRs were also able to recognise endogenously processed peptides and specifically kill HBV-replicating hepatoma cells and strongly reduce cccDNA levels in HBV-infected HepaRG cells.

In addition, intracellular cytokine staining after stimulation showed that the TCR-transduced CD8<sup>+</sup> T cells were polyfunctional, secreting INF- $\gamma$ , TNF- $\alpha$  and IL-2, whereas CD4<sup>+</sup> T cells produced mainly TNF- $\alpha$  and/or IL-2.

We will further analyse our HBV-specific TCRs in HBV/HLA-A2 transgenic mice in order to identify the TCR that confers best antiviral activity. Our HBV-specific TCRs may be used for elucidating specific anti-HBV mechanisms exerted by T cells, and most importantly, for adoptive T cell therapy of chronic hepatitis B and HBV-induced HCC.

## Authors' details

<sup>1</sup>TU Muenchen / Helmholtz Zentrum Muenchen, Institute of Virology, Muenchen, Germany. <sup>2</sup>Klinikum rechts der Isar, III. Medizinische Klinik, Muenchen, Germany. <sup>3</sup>Max-Delbrück Center for Molecular Medicine, Berlin, Germany. <sup>4</sup>TU Muenchen, Institute for Medical Microbiology Immunology and Hygiene, Muenchen, Germany.

Published: 12 March 2014

doi:10.1186/2051-1426-2-S2-P47

**Cite this article as:** Krebs et al.: P73. Functional characterisation of HBV-specific T cell receptors for redirection of T cells against HBV infected hepatocytes. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 2):P47.

<sup>1</sup>TU Muenchen / Helmholtz Zentrum Muenchen, Institute of Virology, Muenchen, Germany

Full list of author information is available at the end of the article